Technologies like cheap genomic sequencing are enabling patients to receive entirely customized therapy based on their genetic, molecular, and metabolic makeup. Personalized medicine will both increase patient outcomes and decrease side effects and unwanted complications. Prominent considerations of the role of pharmacists in health care management include the distribution of drugs and supplies, delivering drug-related information, and consultation to meet the needs of patients and health team members so their role is also very prominent in personalized medicine in the future.
The growing field of Personalized therapy and newer approaches for dosage forms related to Personalization for the safe and effective treatment of patients. The field of personalized medicine aims at converting the term of "one drug fits all " approach to Personalized therapy. Thus, shifting emphasis in medicine from reaction to prevention.
Personalized medicine (PM) aims to individualize treatment based on a person's genes, environment, and lifestyle. It involves analyzing a person's genetic, genomic, and clinical information to make predictions about disease susceptibility, progression, and best treatment options. PM is not just about genetics but also considers natural variations in how individuals metabolize and respond to drugs. Through molecular analysis of biomarkers, PM can classify disease subtypes and subgroups that respond differently to therapies. The goals of PM are to enable more informed healthcare decisions, improve outcomes through targeted therapies, reduce side effects, focus on prevention over reaction, allow for earlier intervention, and reduce costs through a more personalized approach.
1. Dialysis and hemofiltration are methods used to remove drugs and toxins from the bloodstream of patients with end-stage renal disease or drug overdoses.
2. They work by diffusing or conveying waste products across a semi-permeable membrane from the blood into dialysate fluid or through ultrafiltration.
3. The effectiveness of these methods depends on factors like the drug's molecular weight, protein binding, and volume of distribution within the body.
This document outlines a protocol for conducting a therapeutic drug monitoring study, including sections for the title, investigators, study location, patient recruitment details, need for the study, objectives, patient selection criteria, procedures for blood sample collection and storage, instruments for measuring drug and clinical levels, report preparation, clinical interpretation, and conclusion.
Personalized medicine involves the prescription of specific therapeutics best suited for an individual based on their genetic or proteomic profile. This talk discusses current approaches in drug discovery/development, the role of genetics in drug metabolism, and lawful/ethical issues surrounding the deployment of new health technology. I highlight some bioinformatic roles in the drug discovery process, and discuss the use of semantic web technologies for data integration and knowledge discovery..
Pharmacogenomics, Pharmacogenetics and Pharmacokinetics Zohaib HUSSAIN
Introduction
With the information available about human genome and human proteome, it is now well understood that there are a lot of variations between individuals. These minor variations account for many differences like adverse drug reactions, which are responsible for many hospitalizations and casualties. The observed variable effect of drug is due to difference in sensitivity as some people need higher dose and some need lower dose to get similar therapeutic effect, but in some people drug has no therapeutic effects and in some it shows strong adverse reactions.
Pharmaceutical care involves a pharmacist working with a patient and other healthcare providers to design and implement a therapeutic plan to achieve specific outcomes for the patient. This includes identifying potential drug problems, resolving actual problems, and preventing potential problems. The pharmacist must collect patient data, identify issues, establish goals in a treatment plan, evaluate alternatives, individualize regimens, and monitor outcomes. Providing pharmaceutical care improves patient quality of life by curing diseases, reducing symptoms, slowing disease progression, and preventing illness.
The growing field of Personalized therapy and newer approaches for dosage forms related to Personalization for the safe and effective treatment of patients. The field of personalized medicine aims at converting the term of "one drug fits all " approach to Personalized therapy. Thus, shifting emphasis in medicine from reaction to prevention.
Personalized medicine (PM) aims to individualize treatment based on a person's genes, environment, and lifestyle. It involves analyzing a person's genetic, genomic, and clinical information to make predictions about disease susceptibility, progression, and best treatment options. PM is not just about genetics but also considers natural variations in how individuals metabolize and respond to drugs. Through molecular analysis of biomarkers, PM can classify disease subtypes and subgroups that respond differently to therapies. The goals of PM are to enable more informed healthcare decisions, improve outcomes through targeted therapies, reduce side effects, focus on prevention over reaction, allow for earlier intervention, and reduce costs through a more personalized approach.
1. Dialysis and hemofiltration are methods used to remove drugs and toxins from the bloodstream of patients with end-stage renal disease or drug overdoses.
2. They work by diffusing or conveying waste products across a semi-permeable membrane from the blood into dialysate fluid or through ultrafiltration.
3. The effectiveness of these methods depends on factors like the drug's molecular weight, protein binding, and volume of distribution within the body.
This document outlines a protocol for conducting a therapeutic drug monitoring study, including sections for the title, investigators, study location, patient recruitment details, need for the study, objectives, patient selection criteria, procedures for blood sample collection and storage, instruments for measuring drug and clinical levels, report preparation, clinical interpretation, and conclusion.
Personalized medicine involves the prescription of specific therapeutics best suited for an individual based on their genetic or proteomic profile. This talk discusses current approaches in drug discovery/development, the role of genetics in drug metabolism, and lawful/ethical issues surrounding the deployment of new health technology. I highlight some bioinformatic roles in the drug discovery process, and discuss the use of semantic web technologies for data integration and knowledge discovery..
Pharmacogenomics, Pharmacogenetics and Pharmacokinetics Zohaib HUSSAIN
Introduction
With the information available about human genome and human proteome, it is now well understood that there are a lot of variations between individuals. These minor variations account for many differences like adverse drug reactions, which are responsible for many hospitalizations and casualties. The observed variable effect of drug is due to difference in sensitivity as some people need higher dose and some need lower dose to get similar therapeutic effect, but in some people drug has no therapeutic effects and in some it shows strong adverse reactions.
Pharmaceutical care involves a pharmacist working with a patient and other healthcare providers to design and implement a therapeutic plan to achieve specific outcomes for the patient. This includes identifying potential drug problems, resolving actual problems, and preventing potential problems. The pharmacist must collect patient data, identify issues, establish goals in a treatment plan, evaluate alternatives, individualize regimens, and monitor outcomes. Providing pharmaceutical care improves patient quality of life by curing diseases, reducing symptoms, slowing disease progression, and preventing illness.
Causality assessment in the context of adverse events or drug-related effects often involves the use of standardized scales or criteria to determine the likelihood of a causal relationship between a specific intervention (e.g., drug exposure) and an observed outcome. These scales aim to provide a systematic and structured approach to evaluate causality, considering various factors and criteria.
Centralized computer systems are increasingly used in pharmacies. They allow for complete patient medication profiles to be stored digitally, alerting to allergies and drug interactions. Computerized physician order entry systems reduce prescription errors but can still result in dosing mistakes. Robots are used in hospital pharmacies to automate filling prescriptions and verifying labels. Telepharmacy permits remote filling and consultation through computer networks. Centralized systems make information widely available for research while protecting patient privacy. Overall, information technology is transforming pharmacy work through automation and expanded access to care.
This document discusses drug interactions, including definitions, types, mechanisms, high risk patients, and how to handle interactions. It notes the main types are drug-drug, herbal-drug, food-drug, and drink-drug interactions. Mechanisms include effects on absorption, distribution, metabolism, and excretion. Absorption can be affected by changes in pH, bacteria, insoluble complexes, or gastrointestinal motility. Metabolism interactions are through enzyme induction or inhibition. The document provides examples of interactions and notes some drugs are more prone to interactions. It outlines approaches to preventing or managing interactions.
The Indian pharmaceutical industry is growing rapidly but faces challenges in managing its complex supply chain. Drugs are distributed through multiple layers including clearing and forwarding agents, stockists, sub-stockists, and retailers before reaching consumers. This multilayered system makes recalling drugs difficult and increases supply chain costs. Pharmaceutical companies are working to improve supply chain efficiency and ensure quality through initiatives like replenishment-based systems and cold-chain management. Effectively addressing India's fragmented distribution challenges will benefit patients and the healthcare system.
It include the introduction about 3d pharmaceutical how it works and their different types model used in the manufacturing and their applications in medical
This document discusses personalized medicine and provides an outline of topics covered. It defines personalized medicine as tailoring medical treatment to an individual's characteristics. Key areas discussed include pharmacogenetics, how genes and genetic variations affect drug responses, and examples of genetic screening and biomarkers used in drug labeling. The document also addresses challenges in implementing personalized medicine and steps needed like educating healthcare professionals in pharmacogenomics.
This document discusses drug interactions, which can occur via pharmacokinetic or pharmacodynamic mechanisms. Pharmacokinetic interactions involve effects on absorption, distribution, metabolism, or excretion of one drug by another drug. Common examples include inhibition of cytochrome P450 enzymes, alteration of gut motility, and displacement from plasma protein binding sites. Pharmacodynamic interactions involve direct effects on physiological systems or receptor sites, and can result in synergism, antagonism, or unexpected toxicity. It is important for clinicians to be aware of potential drug interactions due to their impact on treatment outcomes and patient safety.
The presentation gives you a bird eye's view regarding basics of PK-PD modeling, its applications, types, limitations and various softwares used for the same.
This document presents information on manufacturing bulk and sterile drugs. It discusses the benefits of in-house manufacturing which includes developing relationships between pharmacists and physicians, promoting cost-effectiveness, and making unavailable drugs accessible. Requirements for manufacturing like facilities, equipment, staffing, and costs are outlined. Bulk compounding and sterile manufacturing are compared, with sterile production requiring more stringent sterility and environmental controls. Precautions for sterile areas like personnel health and attire are also summarized.
Pharmacogenetics involves studying genetic variations that lead to differences in individual drug responses. The goals are to optimize drug therapy and limit toxicity based on a person's genetic profile by choosing the best drug, dose, and duration for that individual. Genetic variations can occur as single nucleotide polymorphisms, which are single base pair differences between individuals. Polymorphisms in genes encoding drug-metabolizing enzymes, such as CYP2D6 and CYP2C9, are clinically significant as they can result in poor, intermediate, extensive, or ultrarapid metabolism of certain drugs. This can impact treatment outcomes and risk of adverse effects.
This document discusses drug interactions, their mechanisms and outcomes. It defines a drug interaction as a modification of one drug's effects due to another substance. Risks include narrow therapeutic indices, polypharmacy, multiple prescribers and patient factors. Outcomes are toxicity, therapeutic failure, beneficial effects or physical incompatibilities. Mechanisms are pharmacokinetic - affecting absorption, distribution, metabolism and excretion - or pharmacodynamic, changing receptor interactions. Specific examples are provided to illustrate different interaction types.
This document discusses dose adjustment in patients with renal impairment. It covers several key topics:
1. The kidney's role in regulating fluids, electrolytes, waste removal, and drug excretion. Impaired kidney function affects drug pharmacokinetics.
2. Approaches for dose adjustment based on estimating remaining renal function and drug clearance. Dose, dosing interval, or both may be adjusted to maintain therapeutic drug levels.
3. Methods for estimating glomerular filtration rate and measuring kidney function using markers like inulin, creatinine, and urea. Creatinine clearance is commonly used in clinical practice.
4. Considerations for dose adjustment in patients on dialysis, as
This document discusses factors that contribute to variability in individual drug responses and the need to individualize drug dosing regimens. It outlines several key sources of variability, including age, body weight, gender, genetics, disease conditions, and drug interactions. For each factor, it provides examples of how that factor can influence the pharmacokinetics and pharmacodynamics of drugs and necessitate dosage adjustments tailored to the individual patient. The goal is to achieve effective therapy while avoiding toxicity by understanding and accounting for variability between patients.
Gentamicin is an aminoglycoside antibiotic commonly used to treat infections caused by Pseudomonas aeruginosa. It has a narrow therapeutic window, and therapeutic drug monitoring (TDM) of peak and trough plasma levels is essential to avoid toxic side effects of nephrotoxicity and ototoxicity. Gentamicin's volume of distribution is low and it is eliminated renally without metabolism. Dosing is based on creatinine clearance and body weight, with peak levels below 12 mg/L and trough levels below 2 mg/L for multiple daily doses, while once daily dosing requires different monitoring approaches.
The document provides an overview of clinical pharmacy, including:
- The historical background and origin of clinical pharmacy.
- Definitions of key terms like clinical pharmacy, pharmaceutical care, and medication-related problems.
- The objectives and benefits of clinical pharmacy and pharmaceutical care in optimizing patient outcomes.
- The roles and functions of clinical pharmacists in areas like establishing need for drug therapy, selecting medicines, administering therapy, monitoring patients, and providing education.
Pharmacogenetics is the study of genetic basis of variation in drug response. It aims to maximize drug efficacy and minimize toxicity. Genetic and exogenous factors contribute to differences in how individuals respond to drugs. Pharmacogenetics can help identify patient subgroups likely to respond to a drug, which aids drug development and allows for customized prescriptions to improve outcomes. It offers advantages like predicting responses, reducing adverse events, and improving rational drug design.
A hospital may manufacture sterile and non-sterile products internally based on economic factors and patient needs. For sterile products like parenterals, the hospital needs facilities for clean rooms, environmental controls, and sterilization methods like UV irradiation. Production planning involves cleaning equipment and containers, preparing solutions/suspensions, filtration, filling, sealing, and sterility testing. Non-sterile manufacturing follows less stringent rules but can still be economical for high-volume needs like oral liquids. The type and size of a hospital determines what products it manufactures internally.
DDS personalised medicines M.Pharma 1st Sem Pharmaceutics.pptxkushaltegginamani18
The document discusses personalized medicines and customized drug delivery systems. It defines personalized medicine as using genetic profiling and other individual patient characteristics to guide medical treatment. Customized drug delivery systems aim to optimize drug therapy for each patient by controlling dosage and delivery through technologies like bioelectronic medicines, 3D printing of pharmaceuticals, and telepharmacy.
Personalized Medicine Pharmacogenomics-.pptAiswaryaA41
The document discusses personalized medicine and pharmacogenomics. It defines key terms like personalized medicine, pharmacogenomics, and pharmacogenetics. Personalized medicine aims to tailor treatment to an individual's unique genetic characteristics and biomarkers to improve health outcomes. The Precision Medicine Initiative launched by President Obama aims to advance this approach. Examples are provided of drugs like warfarin and abacavir where genetic testing can optimize dosing and reduce adverse reactions. Challenges include integrating pharmacogenomics into clinical practice and addressing ethical issues, but personalized medicine may improve drug development and patient care.
Causality assessment in the context of adverse events or drug-related effects often involves the use of standardized scales or criteria to determine the likelihood of a causal relationship between a specific intervention (e.g., drug exposure) and an observed outcome. These scales aim to provide a systematic and structured approach to evaluate causality, considering various factors and criteria.
Centralized computer systems are increasingly used in pharmacies. They allow for complete patient medication profiles to be stored digitally, alerting to allergies and drug interactions. Computerized physician order entry systems reduce prescription errors but can still result in dosing mistakes. Robots are used in hospital pharmacies to automate filling prescriptions and verifying labels. Telepharmacy permits remote filling and consultation through computer networks. Centralized systems make information widely available for research while protecting patient privacy. Overall, information technology is transforming pharmacy work through automation and expanded access to care.
This document discusses drug interactions, including definitions, types, mechanisms, high risk patients, and how to handle interactions. It notes the main types are drug-drug, herbal-drug, food-drug, and drink-drug interactions. Mechanisms include effects on absorption, distribution, metabolism, and excretion. Absorption can be affected by changes in pH, bacteria, insoluble complexes, or gastrointestinal motility. Metabolism interactions are through enzyme induction or inhibition. The document provides examples of interactions and notes some drugs are more prone to interactions. It outlines approaches to preventing or managing interactions.
The Indian pharmaceutical industry is growing rapidly but faces challenges in managing its complex supply chain. Drugs are distributed through multiple layers including clearing and forwarding agents, stockists, sub-stockists, and retailers before reaching consumers. This multilayered system makes recalling drugs difficult and increases supply chain costs. Pharmaceutical companies are working to improve supply chain efficiency and ensure quality through initiatives like replenishment-based systems and cold-chain management. Effectively addressing India's fragmented distribution challenges will benefit patients and the healthcare system.
It include the introduction about 3d pharmaceutical how it works and their different types model used in the manufacturing and their applications in medical
This document discusses personalized medicine and provides an outline of topics covered. It defines personalized medicine as tailoring medical treatment to an individual's characteristics. Key areas discussed include pharmacogenetics, how genes and genetic variations affect drug responses, and examples of genetic screening and biomarkers used in drug labeling. The document also addresses challenges in implementing personalized medicine and steps needed like educating healthcare professionals in pharmacogenomics.
This document discusses drug interactions, which can occur via pharmacokinetic or pharmacodynamic mechanisms. Pharmacokinetic interactions involve effects on absorption, distribution, metabolism, or excretion of one drug by another drug. Common examples include inhibition of cytochrome P450 enzymes, alteration of gut motility, and displacement from plasma protein binding sites. Pharmacodynamic interactions involve direct effects on physiological systems or receptor sites, and can result in synergism, antagonism, or unexpected toxicity. It is important for clinicians to be aware of potential drug interactions due to their impact on treatment outcomes and patient safety.
The presentation gives you a bird eye's view regarding basics of PK-PD modeling, its applications, types, limitations and various softwares used for the same.
This document presents information on manufacturing bulk and sterile drugs. It discusses the benefits of in-house manufacturing which includes developing relationships between pharmacists and physicians, promoting cost-effectiveness, and making unavailable drugs accessible. Requirements for manufacturing like facilities, equipment, staffing, and costs are outlined. Bulk compounding and sterile manufacturing are compared, with sterile production requiring more stringent sterility and environmental controls. Precautions for sterile areas like personnel health and attire are also summarized.
Pharmacogenetics involves studying genetic variations that lead to differences in individual drug responses. The goals are to optimize drug therapy and limit toxicity based on a person's genetic profile by choosing the best drug, dose, and duration for that individual. Genetic variations can occur as single nucleotide polymorphisms, which are single base pair differences between individuals. Polymorphisms in genes encoding drug-metabolizing enzymes, such as CYP2D6 and CYP2C9, are clinically significant as they can result in poor, intermediate, extensive, or ultrarapid metabolism of certain drugs. This can impact treatment outcomes and risk of adverse effects.
This document discusses drug interactions, their mechanisms and outcomes. It defines a drug interaction as a modification of one drug's effects due to another substance. Risks include narrow therapeutic indices, polypharmacy, multiple prescribers and patient factors. Outcomes are toxicity, therapeutic failure, beneficial effects or physical incompatibilities. Mechanisms are pharmacokinetic - affecting absorption, distribution, metabolism and excretion - or pharmacodynamic, changing receptor interactions. Specific examples are provided to illustrate different interaction types.
This document discusses dose adjustment in patients with renal impairment. It covers several key topics:
1. The kidney's role in regulating fluids, electrolytes, waste removal, and drug excretion. Impaired kidney function affects drug pharmacokinetics.
2. Approaches for dose adjustment based on estimating remaining renal function and drug clearance. Dose, dosing interval, or both may be adjusted to maintain therapeutic drug levels.
3. Methods for estimating glomerular filtration rate and measuring kidney function using markers like inulin, creatinine, and urea. Creatinine clearance is commonly used in clinical practice.
4. Considerations for dose adjustment in patients on dialysis, as
This document discusses factors that contribute to variability in individual drug responses and the need to individualize drug dosing regimens. It outlines several key sources of variability, including age, body weight, gender, genetics, disease conditions, and drug interactions. For each factor, it provides examples of how that factor can influence the pharmacokinetics and pharmacodynamics of drugs and necessitate dosage adjustments tailored to the individual patient. The goal is to achieve effective therapy while avoiding toxicity by understanding and accounting for variability between patients.
Gentamicin is an aminoglycoside antibiotic commonly used to treat infections caused by Pseudomonas aeruginosa. It has a narrow therapeutic window, and therapeutic drug monitoring (TDM) of peak and trough plasma levels is essential to avoid toxic side effects of nephrotoxicity and ototoxicity. Gentamicin's volume of distribution is low and it is eliminated renally without metabolism. Dosing is based on creatinine clearance and body weight, with peak levels below 12 mg/L and trough levels below 2 mg/L for multiple daily doses, while once daily dosing requires different monitoring approaches.
The document provides an overview of clinical pharmacy, including:
- The historical background and origin of clinical pharmacy.
- Definitions of key terms like clinical pharmacy, pharmaceutical care, and medication-related problems.
- The objectives and benefits of clinical pharmacy and pharmaceutical care in optimizing patient outcomes.
- The roles and functions of clinical pharmacists in areas like establishing need for drug therapy, selecting medicines, administering therapy, monitoring patients, and providing education.
Pharmacogenetics is the study of genetic basis of variation in drug response. It aims to maximize drug efficacy and minimize toxicity. Genetic and exogenous factors contribute to differences in how individuals respond to drugs. Pharmacogenetics can help identify patient subgroups likely to respond to a drug, which aids drug development and allows for customized prescriptions to improve outcomes. It offers advantages like predicting responses, reducing adverse events, and improving rational drug design.
A hospital may manufacture sterile and non-sterile products internally based on economic factors and patient needs. For sterile products like parenterals, the hospital needs facilities for clean rooms, environmental controls, and sterilization methods like UV irradiation. Production planning involves cleaning equipment and containers, preparing solutions/suspensions, filtration, filling, sealing, and sterility testing. Non-sterile manufacturing follows less stringent rules but can still be economical for high-volume needs like oral liquids. The type and size of a hospital determines what products it manufactures internally.
DDS personalised medicines M.Pharma 1st Sem Pharmaceutics.pptxkushaltegginamani18
The document discusses personalized medicines and customized drug delivery systems. It defines personalized medicine as using genetic profiling and other individual patient characteristics to guide medical treatment. Customized drug delivery systems aim to optimize drug therapy for each patient by controlling dosage and delivery through technologies like bioelectronic medicines, 3D printing of pharmaceuticals, and telepharmacy.
Personalized Medicine Pharmacogenomics-.pptAiswaryaA41
The document discusses personalized medicine and pharmacogenomics. It defines key terms like personalized medicine, pharmacogenomics, and pharmacogenetics. Personalized medicine aims to tailor treatment to an individual's unique genetic characteristics and biomarkers to improve health outcomes. The Precision Medicine Initiative launched by President Obama aims to advance this approach. Examples are provided of drugs like warfarin and abacavir where genetic testing can optimize dosing and reduce adverse reactions. Challenges include integrating pharmacogenomics into clinical practice and addressing ethical issues, but personalized medicine may improve drug development and patient care.
Transalational Sciences and Clinical Pharmacology in Orphan Drug DevelopmentE. Dennis Bashaw
This document discusses challenges and solutions for developing orphan drugs and implementing precision medicine programs. It notes that orphan drug development faces resource constraints as trials require more patients than rare diseases have. However, using clinical pharmacology tools allows learning from small populations by incorporating biomarkers, modeling, and innovative designs. The future of drug development lies in going beyond traditional trials to involve patients more and continually learn from individual experiences. Quantitative tools during all stages of development can extract maximum knowledge from minimal data to improve understanding, approval chances, and labeling.
Pharmacogenomics examines genetic variations that influence individual drug responses. Single nucleotide polymorphisms (SNPs) can predict good, bad, or no response to a drug. DNA microarrays efficiently identify SNPs to personalize treatment. This allows excluding non-responsive patients from trials, improving drug safety and efficacy. Currently, pharmacogenomics guides cancer treatment and medications metabolized by cytochrome P450 enzymes to prevent overdosing. Benefits include tailored therapy and safer drugs, though complexity challenges wide implementation.
Special topic genomics and personalized medicinewatsonma12
This document discusses the emerging field of personalized medicine and how genomics is enabling more targeted medical treatments. It provides examples of how genetic testing can identify patients who will benefit from certain drugs, like Herceptin for breast cancer patients with high levels of the HER-2 gene. The document also outlines some technical, social, and ethical challenges to widespread adoption of personalized medicine, such as improving genetic testing technologies, educating physicians, and preventing discrimination based on genetic information.
The document discusses the role of genomics in pharmacogenomics and drug development. It defines key terms like pharmacogenomics and pharmacogenetics. It explains how genomics technologies can help optimize drug efficacy and minimize toxicity by identifying genetic variations that influence individual drug responses. Genomic information from the human genome project can aid drug target identification and reduce bottlenecks in development. Single nucleotide polymorphisms are discussed as the most common genetic variations affecting drug metabolism. The applications of pharmacogenomics in precision medicine to improve drug safety and efficacy are summarized.
Precision medicine is an emerging strategy that considers individual variability in genes, environment, and lifestyle to diagnose, treat, forecast, and prevent disease. As regulatory health authorities begin to develop clearer regulatory pathways in precision medicine, industries must prepare to swiftly adopt to any regulatory changes. This white paper aims to provide a broad overview on the following key topics in precision medicine:
1. Genomics and Pharmacogenetics
2. Precision Medicine vs Personalized Medicine
3. Foundation of Precision Medicine as A Treatment Tool
4. Examples of Precision Medicine as A Treatment, Predictive, and Preventative Tool
5. Precision Medicine and Cancer
6. Challenges, Next Step & Opportunities in Precision Medicine
7. Regulatory insight on Precision medicine
Pharmacogenomics- a step to personalized medicinesApusi Chowdhury
Pharmacogenomics aims to optimize drug therapy based on a patient's genotype to maximize efficacy and minimize adverse effects. It involves studying how genetic factors influence individual responses to drugs in terms of absorption, distribution, metabolism, and excretion. Genetic polymorphisms like SNPs that occur in over 1% of the population can impact a drug's effects. Pharmacogenomic testing identifies biomarkers related to drug metabolism and targets to determine effective treatments and dosages for patients. While it holds promise for improving drug development and personalized medicine, limitations include insufficient validation and high costs.
Pharmacogenomics refers to the study of the relationship between specific DNA-sequence variation and drug effect, for example, variation in haplotype versus variation in therapeutic outcome
This document discusses the integration of pharmacogenomics into clinical trials. It defines pharmacogenomics as investigating drug responses based on genes, with the goal of predicting side effects and making personalized drug therapy. The causes of using pharmacogenomics in clinical trials include increasing drug failures, costs, and complex diseases. Pharmacogenomics can contribute to innovation in drug discovery and development by allowing targeted drugs tailored to individuals. However, challenges include a lack of standard methods and high costs. Overall, pharmacogenomics holds promise for the future by enabling precision medicine through rigorous research.
This document discusses personalized medicine (PM), which aims to provide customized treatment and care based on a patient's genetic profile. PM considers how genetic variations affect an individual's response to medications and susceptibility to diseases. The document outlines key benefits of PM, such as improved medication selection and safer dosing to minimize adverse reactions. It also discusses some current genetic tests used in PM, such as tests for enzymes involved in drug metabolism. Overall, the document presents PM as a promising approach that may enable more effective, targeted treatment tailored to individual patients.
Pharmacogenomics shows promise for improving patient outcomes and safety by enabling more personalized treatment approaches based on a patient's genetics. However, fully realizing its benefits faces several challenges, including the need for healthcare stakeholders to coordinate effectively, securing adequate resources, and educating physicians on pharmacogenomics. Additionally, drug interactions and environmental factors can complicate the relationship between genetics and drug response, requiring more research before pharmacogenomic testing can be widely implemented in clinical practice.
A biomarker strategy aims to answer key clinical questions to support drug development through identifying and testing biomarkers. Developing a robust biomarker strategy can mitigate risks and inform clinical study design by generating testable hypotheses to bridge pre-clinical and clinical research. Effective biomarker strategies consider assay suitability, study design, and sample availability to reliably detect biomarkers and provide statistically meaningful results. Emerging technologies allow deeper interrogation of drugs and disease through multiplexed readouts to enhance biomarker discovery and clinical development.
The document discusses recent advances in biosimilars and their future prospects. It begins with an abstract about a student's seminar presentation on personalized medicine and pharmacogenomics. The contents section lists topics like what biosimilars are, literature reviews on the use of targeted drugs and clinical trials, the need for and advantages of personalized medicine, and case studies on using genetic testing to target lung cancer treatments. It explores how pharmacogenomics can optimize drug responses based on a patient's genetics and discusses patents and the future of personalized healthcare.
Personalized medicine, Pharmacogenomics, customized drug delivery systems,3d ...Naveen Reddy
Personalized medicine aims to improve health care by integrating information about a person's genes, proteins, and other factors to tailor medical treatment. This includes using genetic or other tests to select treatments, determine dosage, and predict drug responses. Pharmacogenomics plays an important role by identifying genetic factors that influence how individuals respond to medications to optimize treatment and avoid adverse reactions. Emerging areas of personalized medicine include 3D printing of customized drug delivery systems, remote pharmacy services through telepharmacy, and bioelectronic medicines that use electrical stimulation to treat diseases.
Pharmacogenomics aims to optimize drug therapy based on a patient's genotype. Genetic factors can account for 20-95% of variability in drug response. Polymorphisms like SNPs that occur in over 1% of a population can impact drug metabolism and effects. Pharmacogenomic testing targets biomarkers for specific drug classes to determine efficacy and avoid toxicity. While it has potential to improve prescribing, limitations include many genes influencing drugs and ethical issues. Personalized medicine based on pharmacogenomics is still developing.
This document discusses orphan drugs and rare disease drug development. It outlines the challenges in developing drugs for rare diseases, including small patient populations and lack of knowledge. The role of clinical pharmacology in drug development is described, including use of innovative analyses, trial designs, and knowledge management to help overcome challenges. Clinical pharmacology can point the way by applying lessons from oncology and pediatric drug models to the orphan drug context. Collaboration across different stakeholders is needed to develop safe and effective drugs for rare diseases.
We can aid decision making from the pre-clinical to the clinical setting, supporting line of sight to the clinic, by identifying and translating crucial biomarker approaches into the real world.
Know the difference between Endodontics and Orthodontics.Gokuldas Hospital
Your smile is beautiful.
Let’s be honest. Maintaining that beautiful smile is not an easy task. It is more than brushing and flossing. Sometimes, you might encounter dental issues that need special dental care. These issues can range anywhere from misalignment of the jaw to pain in the root of teeth.
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
Travel Clinic Cardiff: Health Advice for International TravelersNX Healthcare
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
The skin is the largest organ and its health plays a vital role among the other sense organs. The skin concerns like acne breakout, psoriasis, or anything similar along the lines, finding a qualified and experienced dermatologist becomes paramount.
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7shruti jagirdar
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfRahul Sen
Time-lapse embryo monitoring is an advanced imaging technique used in IVF to continuously observe embryo development. It captures high-resolution images at regular intervals, allowing embryologists to select the most viable embryos for transfer based on detailed growth patterns. This technology enhances embryo selection, potentially increasing pregnancy success rates.
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
PGx Analysis in VarSeq: A User’s PerspectiveGolden Helix
Since our release of the PGx capabilities in VarSeq, we’ve had a few months to gather some insights from various use cases. Some users approach PGx workflows by means of array genotyping or what seems to be a growing trend of adding the star allele calling to the existing NGS pipeline for whole genome data. Luckily, both approaches are supported with the VarSeq software platform. The genotyping method being used will also dictate what the scope of the tertiary analysis will be. For example, are your PGx reports a standalone pipeline or would your lab’s goal be to handle a dual-purpose workflow and report on PGx + Diagnostic findings.
The purpose of this webcast is to:
Discuss and demonstrate the approaches with array and NGS genotyping methods for star allele calling to prep for downstream analysis.
Following genotyping, explore alternative tertiary workflow concepts in VarSeq to handle PGx reporting.
Moreover, we will include insights users will need to consider when validating their PGx workflow for all possible star alleles and options you have for automating your PGx analysis for large number of samples. Please join us for a session dedicated to the application of star allele genotyping and subsequent PGx workflows in our VarSeq software.
Pictorial and detailed description of patellar instability with sign and symptoms and how to diagnose , what investigations you should go with and how to approach with treatment options . I have presented this slide in my 2nd year junior residency in orthopedics at LLRM medical college Meerut and got good reviews for it
After getting it read you will definitely understand the topic.
1. Role of Pharmacists in Patient
care and Personalized
Medication
Dr. Kamal Singh Rathore
BN College of Pharmacy, BN university, Udaipur
Presented Online with Alwar Pharmacy College , Alwar-Raj.
On
May 10, 2021
5/13/2021 1
2. One Size Doesn’t Fit All..
• Every year in the USA 2 million people die due to adverse drug effects
• Drug efficacy is only in 60 % of the population
• Other 40 % have poor drug effects or no effect at all 3
5/13/2021 2
3. The answer is.. Pharmacogenomics/Precision
Medicines/Personalized Medicines/Individualized
medicine/stratified medicine /P4 medicines
in 1902. Sir Archibald Garrod
5/13/2021 3
The tailoring of treatment
to patients dates back at
least to the time of
Hippocrates
8. Pharmacogenomics and Pharmacogenetics
• Genomics – The study of the entire set of genetic instructions found in a cell (DNA)
• Pharmacogenetics (PGt) — The effect of genetic variation on drug response. A discrete inherited
trait related to drug absorption and disposition
• Pharmacogenomics (PGx)— The application of genomics to the study of human variability in drug
response. [The application of genome-wide SNP scans and gene expression analyses]
• Importance !! Made-to-Order Drugs
• Pharmacogenomics shows how genes determine individual variability to drug response and for
Pharmacists it would be easy to predict how a patient may respond to drug, with the help of a
genetic test before prescribing a drug
5/13/2021 8
13. Human Genome Diversity
• As humans, all of us have a similar genetic code, which is nearly 99.9% similar.
The 0.1% difference is what makes us different influences the response to drugs
• SNPs
• These differences are due to change in the DNA sequence, sometimes a mere
change of one alphabet. This is called as Single Nucleotide Polymorphisms or
SNPs. The effect of one alphabet change can be variable; some could have a
profound change in the meaning/function while others may have minimal or no
effect, as shown below:
• e.g. Cattle – Battle; Tumour – Tumor
• SNPs are powerful Tools
• SNPs screening will help in prescription
• “Right drug at the right dose in the right patient”
5/13/2021 13
17. What Makes it Possible?
• Human genome sequencing
• New technologies facilitate handling of data
• A lot of investment in public and private sector
• The future of medicine – so called Personalized Medicine
5/13/2021 17
In personalised medicine, diagnostic testing is often employed for
selecting appropriate and optimal therapies based on the context of
a patient's genetic content or other molecular or cellular analysis.
The use of genetic information has played a major role in certain
aspects of personalized medicine (e.g. pharmacogenomics), and the
term was first coined in the context of genetics, though it has since
broadened to encompass all sorts of personalization measures,
including the use of proteomics, imaging analysis, nanoparticle-based
theranostics, among others.
18. Ongoing Research on CYP
• Cytochrome P450 superfamily of enzymes
Important drug metabolozing enzymes
Bioactivation and metabolism of approximately 75% of drugs gives
CYPs prominence in pharmacogenetics research
Here’s My Sequence ...
More Business in Future..
• Develop new therapies
• Incorporation of genetic information into the diagnosis
of disease and prescription of drugs
5/13/2021 18
33. Role of Pharmacists
• The field of personalized medicine affords multiple opportunities to
pharmacists, and pharmacists have specific knowledge, skills and
abilities that make them uniquely suited to advance the use of
personalized medicine as a clinical tool.
• The pharmacy profession as a whole, however, has been slow to
embrace the concept of clinical pharmacogenetics and is now facing a
critical juncture that can potentially redefine the professional identity
of the pharmacist.
5/13/2021 33
34. Are pharmacists ready for the challenge of
personalized medicine?
• When assessing the readiness of pharmacy for personalized medicine,
one must consider factors that are specific to the individual
pharmacist as well as systematic considerations that allow
pharmacists to successfully integrate personalized medicine into their
individual practice area.
• These include factors such as education and training, competency, an
attitude of engagement and adequate support and guidance.
Personnel, information technology and laboratory infrastructure are
also critical elements that are required, and financially sustainable
practice models must be developed.
5/13/2021 34
35. Important areas required for implementation
of clinical pharmacogenomics
Such as :
• Pharmacy informatics,
• Clinical decision support tool development,
• Database management,
• Development of medication use policies and processes,
• Logistics of genetic testing,
• Research and clinical guideline development.
5/13/2021 35
37. • Pharmacy is a constantly changing profession that requires
pharmacists to adapt their skills as scientific advances continue to
transform the practice of medicine.
• Over the last 100 years, the profession of pharmacy has evolved from
a dispensing model focused on the formulation and delivery of a drug
product to a patient care model focused on individualizing drug
therapy and delivering direct patient care.
5/13/2021 37
38. • The Clinical Pharmacogenetics Implementation Consortium (CPIC), an international
working group of pharmacists, scientists and other health care professionals, has
developed evidence-based clinical guidelines for 35 actionable gene– drug pairs.
• Over the last two decades, the US Food and Drug Administration has added “black box”
warnings for several medications (e.g., abacavir, clopidogrel, carbamazepine),
incorporated genotype-guided dosing algorithms into product labeling and added
pharmacogenetic information to the labels of >150 medications.
• There are even drugs, such as simeprevir for hepatitis C and mipomersen for
homozygous familial hypercholesterolemia, that require pharmacogenetic testing before
they can be prescribed. The costs of genetic testing continue to decrease and
comprehensive genetic tests can be performed for less than $250 US dollars and are
offered in 7% of hospitals in the US. Direct-to-consumer (DTC) genetic testing kits are
also readily available in community pharmacies, and the first DTC test for determining
breast cancer risk was just approved by the US Food and Drug Administration in March
2018.
5/13/2021 38
39. What do pharmacists need to be ready for
personalized medicine
• Education and training
• Demonstrated competency
• Attitude of engagement
• Support and guidance
• Resources and infrastructure
• Evidence of benefit
• Strengths, weaknesses, opportunities and threats [SWOT Analysis]
• Creating a path forward
5/13/2021 39
44. Lab-on-a-chip
• A physician wants to initiate a specific medication according to the
patient's genotype. All he needs is a drop of patient's blood on a
microchip and in a few minutes the SNP of the patient and the
suitable medication is displayed on the screen [lab on chip]
5/13/2021 44
45. HOW CAN WE IMPLEMENT PERSONALIZED MEDICINE?
The human genome was completely sequenced in 2003. The technology for DNA sequencing is
improving and becoming cheaper. Currently, it would cost Rs. 4.00 to 5.00 lakhs to do a whole
genome sequencing. However, in 5–10 years time, this is expected to fall to Rs.50,000 or less. Thus,
every newborn can have his/her blood sample collected soon after birth and the whole genome
sequencing done. This will then help in the following ways:
To identify diseases which the baby is likely to be predisposed to during his/her lifetime. This will
help in initiating strategies to prevent the development of the disease or reduce that risk
substantially.
To identify drugs which are likely to be toxic/cause severe side-effects, so that these drugs can be
flagged in the baby’s record and avoided if there be a need later.
To identify drugs which are more likely to be effective for diseases manifested later during life,
and with minimal side-effects.
To tailor the treatment, based on the biological characteristics of the cancer, if one were to
develop it later in spite of preventive strategies. This will ensure that the most effective drugs
targeted to the specific cancer are given, increasing the cure rates with minimal side-effects.
Thus, instead of casting a traditional horoscope soon after birth, it would be possible and prudent
to get the Genomic Horoscope done for the baby.
5/13/2021 45
46. PM encompasses all sorts of personalization
measures:
• Use of genomics, proteomics, metabolomics for genome,
transcriptomics, protein RNA/DNA sequencing, HTS, phenotyping
screening
• Imaging analysis: fMRI, CT, PET, SPECT, fluorescent markers (QD),
Radiotracers, HR-LCMS
• Nanoparticles based theranostics etc.: deep learning algorhithm,
Fluorescent in-situ hybridization (FISH)
• 3D printing for drug development
• Coding, WES, WGS , Next gen sequencing (NGS) leads to genome
medicines till 2025.
5/13/2021 46
47. Conclusion
• While pharmacists might not be completely ready for the challenge of
pharmacogenetics, they are most certainly up to facing the challenge.
The time is right and the stage is set for pharmacy to embark on
another transformative journey – a journey that will redefine the role
of the pharmacist and will secure a place for pharmacy in the era of
personalized medicine and beyond.
• Individualize drug therapy opens up exciting new opportunities for
pharmacists to expand their clinical roles and responsibilities.
• Personalized medicine has been identified as a key and prospective
approach to “achieve optimal individual health decisions”, therefore
overcoming the challenge of “Engineer better medicines”
5/13/2021 47